Drug transporters are recognized widely for their role in clinical pharmacokinetics and drug–
drug interactions (DDIs). This has provided impetus to the inclusion of transporter substrate …

Therapeutics in 2001, the National Institutes of Health Biomarkers Definitions Working
Group provided an early definition of a biomarker as “a characteristic that is objectively …

Physiologically‐based pharmacokinetic (PBPK) modeling has been extensively used to
quantitatively translate in vitro data and evaluate temporal effects from drug–drug …

The prediction of drug-drug interactions (DDIs) associated with change in clearance for
metabolism is reviewed, particularly focusing on pharmacokinetic theories for prediction …

Drug–drug interactions (DDIs) related to altered drug absorption and plasma protein binding
have received much less attention from regulatory agencies relative to DDIs mediated via …

Transporter‐mediated drug–drug interactions (DDIs) are among the most important of the
clinically relevant pharmacokinetic DDIs. We investigated the validity of a static prediction of …

Transporters govern the access of molecules to cells or their exit from cells, thereby
controlling the overall distribution of drugs to their intracellular site of action. Clinically …

Variations in drug transporter activities, caused by genetic polymorphism and drug–drug
interactions (DDIs), alter the systemic exposure of substrate drugs, leading to differences in …

Recently, increased interest in drug transporters and research in this area has revealed that
drug transporters play an important role in modulating drug absorption, distribution, and …

Quantitative prediction of the in vivo drug–drug interactions (DDIs) caused by metabolic
inhibition, one of the most common DDI mechanisms in clinical practice, has long been …